pegcetacoplan

Apellis abandons ALS drug after study miss
BioPharma Dive
Thu, 05/25/23 - 01:16 pm
Apellis Pharmaceuticals
ALS
clinical trials
pegcetacoplan
Apellis’ immune system drug hits a setback in ALS
BioPharma Dive
Mon, 04/24/23 - 10:12 am
Apellis Pharmaceuticals
clinical trials
ALS
pegcetacoplan
FDA Approves Apellis' Syfovre as First Treatment for Geographic Atrophy
BioSpace
Mon, 02/20/23 - 12:22 pm
Apellis Pharmaceuticals
Syfovre
pegcetacoplan
FDA
geographic atrophy
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
Investors Business Daily
Fri, 11/18/22 - 11:30 am
Apellis Pharmaceuticals
pegcetacoplan
eye disease
geographic atrophy
Apellis Surges By Double Digits As FDA Mulls Its Eye-Disease Treatment
Investors Business Daily
Tue, 07/19/22 - 10:14 am
Apellis Pharmaceuticals
geographic atrophy
FDA
pegcetacoplan
Apellis plots pegcetacoplan FDA filing in blockbuster GA use after revealing 18-month data
Fierce Pharma
Wed, 03/16/22 - 10:37 am
Apellis
pegcetacoplan
geographic atrophy
FDA
Apellis' eye med application on track for next year after FDA OKs inclusion of phase 2 data
Fierce Pharma
Mon, 11/15/21 - 11:51 pm
Apellis Pharmaceuticals
pegcetacoplan
FDA
clinical trials
age-related macular degeneration
Apellis eye drug succeeds in one key study, but falls short in its twin
BioPharma Dive
Thu, 09/9/21 - 11:16 pm
Apellis Pharmaceuticals
FDA
pegcetacoplan
geographic atrophy
Go or no go? Apellis and Heron head for the finish line
EP Vantage
Fri, 04/30/21 - 10:30 am
Apellis
anemia
pegcetacoplan
Heron Therapeutics
HTX-011
FDA
Apellis' Soliris rival gets a date at the FDA for a rare blood disorder, with potentially $400M worth of implications
Endpoints
Mon, 11/16/20 - 10:39 pm
Apellis
pegcetacoplan
PNH
As CEO bounces back from Covid-19, Apellis says FDA meeting clears path to file for an OK on Soliris rival
Endpoints
Thu, 05/21/20 - 10:31 am
Apellis
FDA
PNH
pegcetacoplan
COVID-19
Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels
Reuters
Tue, 01/7/20 - 10:55 am
Apellis Pharmaceuticals
Alexion Pharmaceuticals
PNH
pegcetacoplan
Soliris